☰

Kian Kani, Ph.D. - Publications

Affiliations: 
2006 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Tiemann K, Garri C, Lee SB, Malihi PD, Park M, Alvarez RM, Yap LP, Mallick P, Katz JE, Gross ME, Kani K. Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene. PMID 30575818 DOI: 10.1038/S41388-018-0638-9  0.542
2018 Tiemann K, Garri C, Wang J, Clarke L, Kani K. Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays. Journal of Visualized Experiments : Jove. PMID 30295648 DOI: 10.3791/57779  0.365
2018 Garri C, Howell S, Tiemann K, Tiffany A, Jalali-Yazdi F, Alba MM, Katz JE, Takahashi TT, Landgraf R, Gross ME, Roberts RW, Kani K. Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 9: 27363-27379. PMID 29937991 DOI: 10.18632/Oncotarget.25221  0.534
2018 Hughes NP, Xu L, Nielsen CH, Chang E, Hori SS, Natarajan A, Lee S, Kjær A, Kani K, Wang SX, Mallick P, Gambhir SS. A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers : Section a of Disease Markers. PMID 29689709 DOI: 10.3233/Cbm-171149  0.519
2017 Poon C, Chowdhuri S, Kuo CH, Fang Y, Alenghat FJ, Hyatt D, Kani K, Gross ME, Chung EJ. Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. Acs Biomaterials Science & Engineering. 3: 3273-3282. PMID 29302619 DOI: 10.1021/Acsbiomaterials.7B00600  0.362
2017 Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P. JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines. Molecular Cancer Therapeutics. PMID 28566434 DOI: 10.1158/1535-7163.Mct-16-0564  0.539
2017 Kani K. Quantitative Proteomics Using SILAC. Methods in Molecular Biology (Clifton, N.J.). 1550: 171-184. PMID 28188530 DOI: 10.1007/978-1-4939-6747-6_13  0.302
2015 Frieboes HB, Curtis LT, Wu M, Kani K, Mallick P. Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor. Cancer Informatics. 14: 163-75. PMID 26715830 DOI: 10.4137/Cin.S35374  0.511
2013 Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. The Prostate. 73: 306-15. PMID 22911164 DOI: 10.1002/Pros.22569  0.486
2012 Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, ... ... Kani K, et al. A cross-platform toolkit for mass spectrometry and proteomics. Nature Biotechnology. 30: 918-20. PMID 23051804 DOI: 10.1038/Nbt.2377  0.496
2012 Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proceedings of the National Academy of Sciences of the United States of America. 109: 13237-42. PMID 22733765 DOI: 10.1073/Pnas.1200105109  0.678
2012 Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, et al. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Molecular Cancer Therapeutics. 11: 1071-81. PMID 22411897 DOI: 10.1158/1535-7163.Mct-11-0852  0.555
2012 Kani K, Sordella R, Mallick P. Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays. Methods in Molecular Biology (Clifton, N.J.). 795: 233-53. PMID 21960227 DOI: 10.1007/978-1-61779-337-0_16  0.519
2011 Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. Plos One. 6: e23090. PMID 21829587 DOI: 10.1371/Journal.Pone.0023090  0.512
2011 Vogelsang MS, Kani K, Katz JE, Mallick P. Model-based discovery of circulating biomarkers. Methods in Molecular Biology (Clifton, N.J.). 728: 87-107. PMID 21468942 DOI: 10.1007/978-1-61779-068-3_5  0.513
2011 Zhang Q, Park E, Kani K, Landgraf R. Abstract C58: Heterotetramers of ERBB2 and ERBB3 generate qualitatively distinct signals from heterodimers and provide most of the neuregulin-induced phosphorylation of ERBB2 Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C58  0.59
2008 Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. Journal of Proteome Research. 7: 4031-9. PMID 18707148 DOI: 10.1021/Pr800307M  0.481
2006 Warren CM, Kani K, Landgraf R. The N-terminal domains of neuregulin 1 confer signal attenuation. The Journal of Biological Chemistry. 281: 27306-16. PMID 16825199 DOI: 10.1074/Jbc.M512887200  0.664
2005 Kani K, Park E, Landgraf R. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry. 44: 15842-57. PMID 16313187 DOI: 10.1021/Bi0515220  0.655
2005 Kani K, Warren CM, Kaddis CS, Loo JA, Landgraf R. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. The Journal of Biological Chemistry. 280: 8238-47. PMID 15611073 DOI: 10.1074/Jbc.M410944200  0.675
Show low-probability matches.